The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Next Generation Complement Therapeutics Market: Distribution by Target Disease Indication (Atypical Hemolytic Uremic Syndrome, Cardiac Transplantation Rejection, Cold Agglutinin Disease, COVID-19, Generalized Myasthenia Gravis, Guillain-Barre Syndrome, Hereditary Angioedema, Neuromyelitis Optica and Paroxysmal Nocturnal Hemoglobinuria), Therapeutic Area (Cardiovascular, Genetic, Hematological and Vascular, Infectious, Neurological and Neuromuscular Disorders), Type of Molecule (Biologic and Small Molecule), Target Pathway (Alternate, Classical, Lectin and Terminal Pathway), Type of Therapy (Monotherapy and Combination Therapy), Route of Administration (Intravenous, Oral and Subcutaneous), Key Geographical Regions (North America, Europe and Asia-Pacific): Industry Trends and Global Forecasts, 2022-2035

  • Lowest Price Guaranteed From USD 5,899

  • Published
    February 2022

  • Slides
    131

  • View Count
    1334

Example Insights

Next-Generation-Complement-Therapeutics-Market-Context Next-Generation-Complement-Therapeutics-Market-Development-Pipeline Next-Generation-Complement-Therapeutics-Market-Distribution-by-Status Next-Generation-Complement-Therapeutics-Market-Clinical-Trial-Analysis
Next-Generation-Complement-Therapeutics-Market-Publication-Analysis Next-Generation-Complement-Therapeutics-Market-Academic-Grant-Analysis Next-Generation-Complement-Therapeutics-Market-Patent-Analysis Next-Generation-Complement-Therapeutics-Market-Partnerships-and-Collaborations
Next-Generation-Complement-Therapeutics-Market-Funding-and-Investments Next-Generation-Complement-Therapeutics-Market-Big-Pharma-Players Next-Generation-Complement-Therapeutics-Market-Distribution-by-Type-of-Molecule Next-Generation-Complement-Therapeutics-Market-Distribution-by-Geography

Overview

Since the approval of Soliris® in 2007, an anti-C5 antibody, the field of complement drug discovery has gained significant attention. Currently, nine complement therapeutics are commercially available, while around 190 molecules are under development for various disease indications. Some of the complement therapeutics, namely Berinert®, Cinryze®, ORLADEYO®, Ruconest® and TAKHZYRO® were approved for the treatment of hereditary angioedema, by the US FDA and the EMA. In addition, the complement inhibitor drug, EMPAVELITM (pegcetacoplan), which is the first approved complement C3 inhibitor, developed by Apellis Pharmaceuticals, has been approved by the FDA for the treatment of paroxysmal nocturnal hemoglobinuria; it is believed to bring in new possibilities for the treatment of autoimmune and inflammatory disorders. Discovered in 19th century, complement system is a part of innate immune system and tissue homeostasis, which recognizes, tags and helps to eliminate various disease-causing pathogens. In addition, complement system plays a role in the physiology of a healthy organism (homeostasis) for the removal of apoptotic cells, thereby regulating cell survival. However, inadequate complement activation results in outgrowth of pathogens and suppression of complement regulators, which ultimately becomes a disease cause. As a result, complement-targeted therapeutics have been developed; they inhibit complement activation, thereby reducing tissue inflammation and dampening the adaptive immune response to foreign and tissue antigens.

Several drug developers are actively engaged in the development of next generation complement therapeutics with enhanced efficacy. A variety of molecules, such as biologics, gene therapies, oligonucleotides, small interfering RNAs and small molecule-based complement therapeutics are being developed for the treatment of different disease conditions, including dermatological, genetic, hematological and vascular, immunological and inflammatory, infectious, neurological, ophthalmic, renal disorders. Owing to the fact that the complement system is a multidimensional innate immune surveillance system, more novel therapeutic targets are likely to be discovered in the future. Moreover, the R&D efforts in this field are also being supported by the National Institutes of Health, which have awarded grants worth USD 837 million for research efforts in this domain over the last few years. With the active involvement of big pharma players as well as new entrants, the drug development landscape of the complement therapeutics is likely to expand. Further, with the encouraging clinical research efforts, broadening of disease focus and efforts to go beyond C5 with innovative approaches that could decrease prices and address safety concerns, the complement therapeutics market is poised to witness steady growth over the coming years.

Scope of the Report

The ‘Next Generation Complement Therapeutics Market: Distribution by Target Disease Indication (Atypical Hemolytic Uremic Syndrome, Cardiac Transplantation Rejection, Cold Agglutinin Disease, COVID-19, Generalized Myasthenia Gravis, Guillain-Barre Syndrome, Hereditary Angioedema, Neuromyelitis Optica and Paroxysmal Nocturnal Hemoglobinuria), Therapeutic Area (Cardiovascular, Genetic, Hematological and Vascular, Infectious, Neurological and Neuromuscular Disorders), Type of Molecule (Biologic and Small Molecule), Target Pathway (Alternate, Classical, Lectin and Terminal Pathway), Type of Therapy (Monotherapy and Combination Therapy), Route of Administration  (Intravenous, Oral and Subcutaneous), Key Geographical Regions (North America, Europe and Asia-Pacific): Industry Trends and Global Forecasts, 2022-2035’ report features an extensive study on the current market landscape, offering an informed opinion on the likely evolution of the next generation complement therapeutics in the treatment of various complement-mediated diseases. The study underlines an in-depth analysis, highlighting the diverse capabilities of players engaged in this domain. Amongst other elements, the report includes:

  • A detailed review of the current market landscape of next generation complement therapeutics, based on several relevant parameters, such as status of development (marketed, phase III, phase II / III, phase II, phase I / II, phase I, and preclinical stage), type of molecule (biologic and small molecule), type of drug, biological target, target pathway (alternative, classical, lectin and terminal pathway), mechanism of action, target disease indication(s), therapeutic area(s), route of administration (intrarenal, intravenous, intravitreal, nasal, oral and subcutaneous), type of therapy (monotherapy and combination therapy) and dosing frequency. In addition, it includes a list of next generation complement therapeutics with special designations. Further, the chapter presents a list of players developing next generation complement therapeutics along with information on their year of establishment, company size and location of headquarters. 
  • Detailed profiles of key players engaged in the development of next generation complement therapeutics (shortlisted on the basis of company size). Each profile features a brief overview of the company, its financial information (if available), details on its product portfolio, recent developments and an informed future outlook.
  • An in-depth analysis of completed, ongoing and planned clinical studies of various next generation complement therapeutics, highlighting prevalent trends across different parameters, such as current trial status, trial registration year, trial phase, enrolled patient population, type of sponsor / collaborator, type of study, study design, leading industry and non-industry players (in terms of number of trials conducted), key indication(s), popular therapeutics area(s), type of treatment, type of drug, emerging focus areas and regional distribution of trials.
  • A detailed review of more than 1,450 peer-reviewed, scientific articles related to research on next generation complement therapeutics, which have been published during 2017-2021, based on parameters, such as year of publication, emerging focus areas, top authors, key research journals, popular indication(s) and therapeutic area(s).
  • An in-depth analysis of grants awarded to various research institutes for the projects related to next generation complement therapeutics, during period 2017-2021, on the basis of parameters, such as year of grant awarded, amount awarded, funding institute center, support period, type of grant, activity code, while highlighting popular recipient organizations (in terms of number and amount of grants awarded), popular NIH departments, study section, type of recipient organization, emerging focus areas of the grants, purpose of grant awarded, prominent program officers and location of recipient organizations.
  • An insightful analysis of the patents filed / granted for next generation complement therapeutics, between 2016- 2021, on the basis of various relevant parameters, such as patent publication year, type of patent, geographical location, CPC symbols, type of applicant, patent age, emerging focus areas, leading industry and non-industry players (in terms of number of patents granted / filed) and patent characteristics. In addition, the chapter includes a detailed patent benchmarking and an insightful valuation analysis.
  • An analysis of the partnerships that have been established in this domain since 2014, covering instances of clinical trials agreement, distribution and supply agreement, licensing agreement, product development and commercialization agreement, product development and manufacturing agreement, product distribution and commercialization agreement, research and development agreement, and research, development and commercialization agreement and other relevant types of deals.
  • A detailed analysis of the various funding and investments made since 2014, including venture capital financing, secondary offering, private placement, grant, debt financing and other equity in the companies focused on the development of next generation complement therapeutics.
  • An analysis of big pharma players engaged in the field of next generation complement therapeutics, featuring different insightful representations, such as spider web analysis, Harvey ball analysis and wind rose chart, based on several relevant parameters, such as number of therapeutics under development, type of molecule, status of development, number of therapeutic areas, number of partnerships, number of patents and years of experience.

One of the key objectives of the report was to identify the primary growth drivers and estimate the future growth opportunity associated with next generation complement therapeutics market in the mid to long term. Based on parameters, such as target patient population, likely adoption rates and expected pricing, we have provided informed estimates on the likely evolution of the market for the period 2022-2035.

Our year wise projections of the current and forecasted opportunity within the next generation complement therapeutics market have further been segmented across [A] Target Disease Indications (Atypical Hemolytic Uremic Syndrome, Cardiac Transplantation Rejection, Cold Agglutinin Disease, COVID-19, Generalized Myasthenia Gravis, Guillain-Barre Syndrome, Hereditary Angioedema, Neuromyelitis Optica and Paroxysmal Nocturnal Hemoglobinuria), [B] Therapeutic Areas (Cardiovascular, Genetic, Hematological and Vascular, Infectious, Neurological and Neuromuscular Disorders), [C] Type of Molecule (Biologics and Small Molecules), [D] Target Pathway (Alternate, Classical, Lectin and Terminal Pathway), [E] Type of Therapy (Monotherapy and Combination Therapy), [F] Route of Administration  (Intravenous, Oral and Subcutaneous), [G] Key Geographical Regions (North America, Europe and Asia-Pacific. In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the leading industry and non-industry players engaged in the development of next generation complement therapeutics?
  • Which are the key drugs being developed across early and late stages of development?
  • Which geographies are the most active in conducting clinical trials related to next generation complement therapeutics?
  • What is the focus area of various publications related to the next generation complement therapeutics?
  • Which are the leading funding institutes / centers supporting the research related to next generation complement therapeutics?
  • What kind of partnership models are commonly adopted by industry stakeholders?
  • Who are the key investors, active in the field of next generation complement therapeutics?
  • What are the different initiatives undertaken by big pharma players for the development of next generation complement therapeutics in the recent past?
  • How is the current and future market opportunity, related to next generation complement therapeutics likely to be distributed across key market segments?

Contents

Chapter Outlines

Chapter 2 provides an executive summary of the key insights captured during our research. It offers a high-level view on the likely evolution of the next generation complement therapeutics market in the mid to long term.

Chapter 3 provides a general overview of complement system including information on the immune cells involved in complement system, and sources of key complement proteins. In addition, the chapter presents details on the complement activation pathways (classical, lectin, alternative and terminal pathway). It also features information on consequences of a dysregulated complement system, types of complement therapeutics, limitations and future of next generation complement therapeutics.

Chapter 4 provides an overview of the current market landscape of next generation complement therapeutics, based on several relevant parameters, such as status of development (marketed, phase III, phase II / III, phase II, phase I / II, phase I, and preclinical stage), type of molecule (biologic and small molecule), biological target, target pathway (alternative, classical, lectin and terminal pathway), mechanism of action, target disease indication(s), therapeutic area(s), route of administration (intrarenal, intravenous, intravitreal, nasal, oral and subcutaneous) and type of therapy (monotherapy and combination therapy).

Chapter 5 includes detailed profiles of key players engaged in the development of next generation complement therapeutics. Each profile features a brief overview of the company, its financial information (if available), details on its product portfolio, recent developments and an informed future outlook.

Chapter 6 provides information on more than 870 completed, ongoing and planned clinical studies of next generation complement therapeutics, based on different parameters, such as trial status, trial registration year, trial phase, enrolled patient population, type of sponsor / collaborator, type of study, and study design. In addition, the chapter highlights leading industry and non-industry players, key indication(s), popular therapeutics area(s), type of drug, emerging focus areas and regional distribution of trials. 

Chapter 7 features a detailed review of more than 1,450 peer-reviewed, scientific articles related to research on next generation complement therapeutics, based on parameters, such as year of publication, emerging focus area, top authors, key research journals, popular indication(s) and therapeutic area(s) (in terms of number of articles published).

Chapter 8 provides an in-depth analysis of grants that have been awarded to various research institutes for projects related to next generation complement therapeutics, during 2017-2021, on the basis of important parameters, such as year of grant awarded, amount awarded, funding institute center, support period, type of grant, activity code, while highlighting popular recipient organizations (in terms of number and amount of grants awarded), popular NIH departments, study section. The chapter also highlights type of recipient organization, emerging focus areas of the grants, purpose of grant awarded, prominent program officers and location of recipient organizations.

Chapter 9 features an in-depth analysis of the patents that have been filed / granted for next generation complement therapeutics, between 2016-2021, on the basis of various relevant parameters, such as patent publication year, type of patent, geographical location, CPC symbols, type of applicant, patent age, emerging focus areas, leading industry and non-industry players (in terms of number of patents granted / filed) and patent characteristics. In addition, it includes detailed patent benchmarking and an insightful valuation analysis.

Chapter 10 features an analysis of the partnerships that have been established in this domain, covering instances of clinical trials agreement, distribution and supply agreement, licensing agreement, product development and commercialization agreement, product development and manufacturing agreement, research and development agreements and other relevant types of deals.

Chapter 11 presents detailed analysis of various funding and investments made since 2014, including venture capital financing, secondary offering, private placement, grant, debt financing and other equity in the companies focused on the development of next generation complement therapeutics.

Chapter 12 includes an analysis of big pharma players engaged in the field of next generation complement therapeutics, featuring different insightful representations, such as spider web analysis, Harvey ball analysis and wind rose chart, based on several relevant parameters, such as number of therapeutics under development, type of molecule, status of development, number of therapeutic areas, number of partnerships, number of patents and years of experience.

Chapter 13 presents an insightful market forecast analysis, highlighting the future potential of the next generation complement therapeutics market till the year 2035. It includes future sales projections of next generation complement therapeutics that are either marketed or are likely to be marketed within the next two years. In order to provide a detailed future outlook, our projections have been segmented across (A) Target Disease Indications (Atypical Hemolytic Uremic Syndrome, Cardiac Transplantation Rejection, Cold Agglutinin Disease, COVID-19, Generalized Myasthenia Gravis, Guillain-Barre Syndrome, Hereditary Angioedema, Neuromyelitis Optica and Paroxysmal Nocturnal Hemoglobinuria), (B) Therapeutic Areas (Cardiovascular, Genetic, Hematological and Vascular, Infectious, Neurological and Neuromuscular Disorders), (C) Type of Molecule (Biologics and Small Molecules), (D) Target Pathway (Alternate, Classical, Lectin and Terminal Pathway), (E) Type of Therapy (Monotherapy and Combination Therapy), (F) Route of Administration  (Intravenous, Oral and Subcutaneous), and (G) Key Geographical Regions (North America, Europe and Asia-Pacific). 

Chapter 14 presents expert opinion in the complement therapeutics domain.

Chapter 15 is an appendix that contains tabulated data and numbers for all the figures in the report.

Chapter 16 is an appendix that provides the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Overview of Complement System
3.2. Immune Cells Involved in Complement System
3.3. Characteristics of Complement System
3.4. Functions of Complement System
3.5. Role of Complement in Homeostasis and Stress Conditions
3.6. Activation of Complement System
3.6.1. Steps in Complement Activation
3.7. Sources of Key Complement Proteins
3.8. Functions of Complement Proteins of Classical Pathway
3.9. Pathways of Complement System
3.9.1. Classical Pathway
3.9.2. Lectin Pathway
3.9.3. Alternative Pathway
3.9.4. Terminal Pathway

3.10. Consequences of a Dysregulated Complement System
3.11. Diseases related to Defects in Complement Proteins
3.12. Types of Complement Therapeutics
3.13. Limitations of Complement Therapeutics
3.14. Future of Next Generation Complement Therapeutics

4. NEXT GENERATION COMPLEMENT THERAPEUTICS: MARKET LANDSCAPE
4.1. Analysis Methodology and Key Parameters
4.2. Next Generation Complement Therapeutics: Development Pipeline
4.2.1. Analysis by Status of Development
4.2.2. Analysis by Type of Molecule
4.2.3. Analysis by Status of Development and Type of Molecule
4.2.4. Analysis by Type of Drug
4.2.5. Analysis by Biological Target
4.2.6. Analysis by Target Pathway
4.2.7. Analysis by Mechanism of Action
4.2.8. Analysis by Mechanism of Action and Target Pathway
4.2.9. Analysis by Target Disease Indication(s)
4.2.10. Analysis by Status of Development and Target Disease Indication(s)
4.2.11. Analysis by Therapeutic Area
4.2.12. Analysis by Therapeutic Area and Type of Molecule
4.2.13. Analysis by Route of Administration
4.2.14. Analysis by Type of Therapy
4.2.15. Analysis by Dosing Frequency
4.2.16. Grid Analysis: Type of Therapy, Type of Molecule, Route of Administration and Mechanism of Action

4.3. Next Generation Complement Therapeutics: List of Drugs with Special Designations
4.3.1. Analysis by Special Designation

4.4. Next Generation Complement Therapeutics: Developer Landscape
4.4.1. Analysis by Year of Establishment
4.4.2. Analysis by Company Size
4.4.3. Analysis by Region of Headquarters
4.4.4. Analysis by Company Size and Region of Headquarters
4.4.5. Leading Players: Analysis by Number of Therapeutics

5. COMPANY PROFILES
5.1. Amgen
5.1.1. Company Overview
5.1.2. Financial Information
5.1.3. Product Portfolio
5.1.4. Recent Developments and Future Outlook

5.2. CSL Behring
5.2.1. Company Overview
5.2.2. Financial Information
5.2.3. Product Portfolio
5.2.4. Recent Developments and Future Outlook

5.3. Innovent Biologics
5.3.1. Company Overview
5.3.2. Financial Information
5.3.3. Product Portfolio
5.3.4. Recent Developments and Future Outlook

5.4. Novartis
5.4.1. Company Overview
5.4.2. Financial Information
5.4.3. Product Portfolio
5.4.4. Recent Developments and Future Outlook

5.5. Regeneron
5.5.1. Company Overview
5.5.2. Financial Information
5.5.3. Product Portfolio
5.5.4. Recent Developments and Future Outlook

5.6. Roche
5.6.1. Company Overview
5.6.2. Financial Information
5.6.3. Product Portfolio
5.6.4. Recent Developments and Future Outlook

5.7. Sanofi
5.7.1. Company Overview
5.7.2. Financial Information
5.7.3. Product Portfolio
5.7.4. Recent Developments and Future Outlook

5.8. Takeda
5.8.1. Company Overview
5.8.2. Financial Information
5.8.3. Product Portfolio
5.8.4. Recent Developments and Future Outlook

5.9. UCB
5.9.1. Company Overview
5.9.2. Financial Information
5.9.3. Product Portfolio
5.9.4. Recent Developments and Future Outlook

6. CLINICAL TRIAL ANALYSIS
6.1. Analysis Methodology and Key Parameters
6.2. Next Generation Complement Therapeutics: List of Clinical Trials
6.2.1. Analysis by Trial Status
6.2.2. Cumulative Analysis by Trial Registration Year
6.2.3. Analysis by Trial Registration Year and Status
6.2.4. Analysis by Trial Phase
6.2.5. Analysis by Trial Phase and Patients Enrolled
6.2.6. Analysis by Trial Registration Year and Patients Enrolled
6.2.7. Analysis by Type of Sponsor / Collaborator
6.2.8. Analysis by Type of Study
6.2.9. Analysis by Study Design
6.2.10. Most Active Industry Players: Analysis by Number of Trials
6.2.11. Most Active Non-Industry Players: Analysis by Number of Trials
6.2.12. Analysis by Disease Indication
6.2.13. Most Popular Therapeutic Areas: Analysis by Number of Trials
6.2.14. Analysis by Type of Treatment
6.2.15. Analysis by Type of Drug
6.2.16. Word Cloud Analysis: Emerging Focus Areas
6.2.17. Analysis by Top Indications and Phase of the Trial
6.2.18. Analysis by Top Indications and Leading Industry Players
6.2.19. Analysis by Trial Location
6.2.20. Analysis by Geography and Trial Status

7. PUBLICATION ANALYSIS
7.1. Analysis Methodology and Key Parameters
7.2. Next Generation Complement Therapeutics: List of Publications
7.2.1. Analysis by Year of Publication
7.2.2. Word Cloud Analysis: Emerging Focus Areas
7.2.3. Top Authors: Analysis by Number of Publications
7.2.4. Key Journals based on Number of Publications
7.2.5. Key Journals based on Impact Factor
7.2.6. Popular Indications based on Number of Publications
7.2.7. Popular Therapeutic Areas based on Number of Publications

8. GRANT ANALYSIS
8.1. Analysis Methodology and Key Parameters
8.1.1. Analysis by Year of Grants Awarded
8.1.2. Analysis by Amount Awarded
8.1.3. Analysis by Funding Institute Center
8.1.4. Analysis by Support Period
8.1.5. Analysis by Funding Institute Center and Support Period
8.1.6. Analysis by Type of Grant
8.1.7. Analysis by Activity Code
8.1.8. Popular Recipient Organizations: Analysis by Number of Grants
8.1.9. Popular Recipient Organizations: Analysis by Amount Awarded
8.1.10. Popular NIH Departments: Analysis by Number of Grants
8.1.11. Analysis by Study Section
8.1.12. Analysis by Type of Recipient Organization
8.1.13. Word Cloud Analysis: Emerging Focus Areas
8.1.14. Analysis by Purpose of Grant
8.1.15. Prominent Program Officers: Analysis by Number of Grants
8.1.16. Analysis by Location of Recipient Organizations

9. PATENT ANALYSIS
9.1. Analysis Methodology and Key Parameters
9.2. Next Generation Complement Therapeutics: List of Patents
9.2.1. Analysis by Patent Publication Year
9.2.2. Analysis of Year-wise Granted Patents
9.2.3. Analysis by Type of Patent
9.2.4. Analysis by Granted Patents and Patent Applications
9.2.5. Analysis by Geography
9.2.6. Analysis by CPC Symbols
9.2.7. Analysis by Type of Applicant
9.2.8. Analysis of Patents by Age
9.2.9. Word Cloud Analysis: Emerging Focus Areas
9.2.10. Leading Industry Players: Analysis by Number of Patents
9.2.11. Leading Non-Industry Players: Analysis by Number of Patents
9.2.12. Leading Individual Assignees: Analysis by Number of Patents
9.2.13. Leading Players: Benchmarking by Patent Characteristics (CPC Symbols)
9.2.14. Patent Valuation: Analysis Methodology and Parameters
9.2.15. Patent Valuation: Analysis by Relative Valuation

10. PARTNERSHIPS AND COLLABORATIONS
10.1. Next Generation Complement Therapeutics: List of Partnerships and Collaborations
10.1.1. Analysis by Year-wise Trend of Partnership
10.1.2. Analysis by Type of Partnership
10.1.3. Analysis by Year and Type of Partnership
10.1.4. Most Popular Drug: Analysis by Number of Partnerships
10.1.5. Analysis by Biological Target
10.1.6. Analysis by Target Pathway
10.1.7. Word Cloud Analysis: Emerging Focus Areas
10.1.8. Analysis by Drug and Type of Partnership
10.1.9. Analysis by Type of Partner
10.1.10. Analysis by Popular Disease Indication
10.1.11. Analysis by Popular Disease Indication and Type of Partnership
10.1.12. Analysis by Therapeutic Area
10.1.13. Analysis by Therapeutic Area and Type of Partnership
10.1.14. Regional Analysis of Partnerships
10.1.15. Intercontinental and Intracontinental Agreements

11. FUNDING AND INVESTMENT ANALYSIS
11.1. Next Generation Complement Therapeutics: List of Funding and Investments
11.1.1. Cumulative Year-wise Trend
11.1.2. Analysis by Amount Invested per Year
11.1.3. Analysis by Type of Funding and Year of Establishment
11.1.4. Analysis of Instances by Type of Funding
11.1.5. Analysis of Amount Invested by Type of Funding
11.1.6. Analysis by Year, Type of Funding and Amount Invested
11.1.7. Most Active Investors: Analysis by Number of Instances
11.1.8. Most Active Players: Analysis by Number of Funding Instances
11.1.9. Most Active Players: Analysis by Amount Raised
11.1.10. Analysis of Amount by Drug
11.1.11. Analysis of Number of Instances by Drug
11.1.12. Summary of Investments

12. BIG PHARMA PLAYERS
12.1 Analysis Methodology and Key Parameters
12.2. Scoring of Parameters
12.3. Big Pharma Players: Information on Revenues Generated in 2021
12.3.1. Analysis by Supplier Strength
12.3.2. Analysis by Portfolio Strength
12.3.3. Analysis by Portfolio Diversity
12.3.4. Benchmarking: Spider Web Analysis
12.3.5. Benchmarking: Harvey Ball Analysis
12.3.6. Benchmarking: Wind Rose Chart

13. MARKET SIZING AND OPPORTUNITY ANALYSIS
13.1. Forecast Methodology and Key Parameters
13.2. Global Next Generation Complement Therapeutics Market, 2022-2035
13.3. Global Next Generation Complement Therapeutics Market for Marketed Drugs, 2022-2035
13.3.1. Next Generation Complement Therapeutics Market for Marketed Drugs, 2022-2035: Distribution by Target Disease Indication
13.3.1.1. Next Generation Complement Therapeutics Market for Paroxysmal Nocturnal Hemoglobinuria, 2022-2035
13.3.1.2. Next Generation Complement Therapeutics Market for Hereditary Angioedema, 2022-2035

13.3.2. Next Generation Complement Therapeutics Market for Marketed Drugs, 2022-2035: Distribution by Type of Molecule
13.3.2.1. Next Generation Complement Therapeutics Market for Biologics, 2022-2035
13.3.2.2. Next Generation Complement Therapeutics Market for Small Molecules, 2022-2035

13.3.3. Next Generation Complement Therapeutics Market for Marketed Drugs, 2022-2035: Distribution by Target Pathway
13.3.3.1. Next Generation Complement Therapeutics Market for Terminal Pathway, 2022-2035
13.3.3.2. Next Generation Complement Therapeutics Market for Classical Pathway, 2022-2035
13.3.3.3. Next Generation Complement Therapeutics Market for Alternate Pathway, 2022-2035
13.3.3.4. Next Generation Complement Therapeutics Market for Lectin Pathway, 2022-2035

13.3.4. Next Generation Complement Therapeutics Market for Marketed Drugs, 2022-2035: Distribution by Type of Therapy
13.3.4.1. Next Generation Complement Therapeutics Market for Monotherapy, 2022-2035
13.3.4.2. Next Generation Complement Therapeutics Market for Combination Therapy, 2022-2035

13.3.5. Next Generation Complement Therapeutics Market for Marketed Drugs, 2022-2035: Distribution by Route of Administration
13.3.5.1. Next Generation Complement Therapeutics Market for Intravenous Drugs, 2022-2035
13.3.5.2. Next Generation Complement Therapeutics Market for Subcutaneous Drugs, 2022-2035
13.3.5.3. Next Generation Complement Therapeutics Market for Oral Drugs, 2022-2035

13.4. Product-wise Sales Forecast for Marketed Drugs
13.4.1. Berinert (CSL Behring)
13.4.1.1. Sales Forecast (USD Billion)
13.4.2. EMPAVELI (Apellis Pharmaceuticals)
13.4.2.1. Sales Forecast (USD Billion)
13.4.3. ORLADEYO (BioCryst Pharmaceuticals)
13.4.3.1. Sales Forecast (USD Billion)
13.4.4. Ruconest (Pharming)
13.4.4.1. Sales Forecast (USD Billion)
13.4.5. Soliris (Alexion Pharmaceuticals)
13.4.5.1. Sales Forecast (USD Billion)
13.4.6. Takhzyro (Takeda)
13.4.6.1. Sales Forecast (USD Billion)
13.4.7. Ultomiris (Alexion Pharmaceuticals)
13.4.7.1. Sales Forecast (USD Billion)

13.5. Global Next Generation Complement Therapeutics Market for Phase III Drugs, 2022-2035
13.5.1. Next Generation Complement Therapeutics Market for Phase III Drugs, 2022-2035: Distribution by Target Disease Indication
13.5.1.1. Next Generation Complement Therapeutics Market for Atypical Hemolytic Uremic Syndrome, 2022-2035
13.5.1.2. Next Generation Complement Therapeutics Market for Cardiac Transplantation Rejection, 2022-2035
13.5.1.3. Next Generation Complement Therapeutics Market for Cold Agglutinin Disease, 2022-2035
13.5.1.4. Next Generation Complement Therapeutics Market for COVID-19, 2022-2035
13.5.1.5. Next Generation Complement Therapeutics Market for Guillain-Barre Syndrome, 2022-2035
13.5.1.6. Next Generation Complement Therapeutics Market for Generalized Myasthenia Gravis, 2022-2035
13.5.1.7. Next Generation Complement Therapeutics Market for Neuromyelitis Optica, 2022-2035
13.5.1.8. Next Generation Complement Therapeutics Market for Paroxysmal Nocturnal Hemoglobinuria, 2022-2035

13.5.2. Next Generation Complement Therapeutics Market for Phase III Drugs, 2022-2035: Distribution by Therapeutic Area
13.5.2.1. Next Generation Complement Therapeutics Market for Cardiovascular Disorders, 2022-2035
13.5.2.2. Next Generation Complement Therapeutics Market for Hematological and Vascular Disorders, 2022-2035
13.5.2.3. Next Generation Complement Therapeutics Market for Infectious Diseases, 2022-2035
13.5.2.4. Next Generation Complement Therapeutics Market for Neurological Disorders, 2022-2035
13.5.2.5. Next Generation Complement Therapeutics Market for Neuromuscular Disorders, 2022-2035
13.5.2.6. Next Generation Complement Therapeutics Market for Genetic Disorders, 2022-2035

13.5.3. Next Generation Complement Therapeutics Market for Phase III Drugs, 2022-2035: Distribution by Target Pathway
13.5.3.1. Next Generation Complement Therapeutics Market for Terminal Pathway, 2022-2035
13.5.3.2. Next Generation Complement Therapeutics Market for Lectin Pathway, 2022-2035
13.5.3.3. Next Generation Complement Therapeutics Market for Classical Pathway, 2022-2035

13.5.4. Next Generation Complement Therapeutics Market for Phase III Drugs, 2022-2035: Distribution by Type of Therapy
13.5.4.1. Next Generation Complement Therapeutics Market for Monotherapy, 2022-2035
13.5.4.2. Next Generation Complement Therapeutics Market for Combination Therapy, 2022-2035

13.5.5. Next Generation Complement Therapeutics Market for Phase III Drugs, 2022-2035: Distribution by Route of Administration
13.5.5.1. Next Generation Complement Therapeutics Market for Intravenous Drugs, 2022-2035
13.5.5.2. Next Generation Complement Therapeutics Market for Subcutaneous Drugs, 2022-2035

13.5.6. Next Generation Complement Therapeutics Market for Phase III Drugs, 2022-2035: Distribution by Geography
13.5.6.1. Next Generation Complement Therapeutics Market in North America, 2022-2035
13.5.6.1.1. Next Generation Complement Therapeutics Market in US, 2022-2035
13.5.6.1.2. Next Generation Complement Therapeutics Market in Canada, 2022-2035
13.5.6.2. Next Generation Complement Therapeutics Market in Europe, 2022-2035
13.5.6.2.1. Next Generation Complement Therapeutics Market in UK, 2022-2035
13.5.6.2.2. Next Generation Complement Therapeutics Market in Germany, 2022-2035
13.5.6.2.3. Next Generation Complement Therapeutics Market in France, 2022-2035
13.5.6.2.4. Next Generation Complement Therapeutics Market in Italy, 2022-2035
13.5.6.2.5. Next Generation Complement Therapeutics Market in Spain, 2022-2035
13.5.6.3. Next Generation Complement Therapeutics Market in Asia Pacific, 2022-2035
13.5.6.3.1. Next Generation Complement Therapeutics Market in Australia, 2022-2035
13.5.6.3.2. Next Generation Complement Therapeutics Market in Japan, 2022-2035
13.5.6.3.3. Next Generation Complement Therapeutics Market in China, 2022-2035
13.5.6.3.4. Next Generation Complement Therapeutics Market in India, 2022-2035

13.6. Product-wise Sales Forecast for Phase III Drugs
13.6.1. Narsoplimab (Omeros)
13.6.1.1. Target Patient Population
13.6.1.2. Sales Forecast (USD Billion)
13.6.1.3. Net Present Value (USD Billion)
13.6.1.4. Value Creation Analysis
13.6.2. REGN3918 (Regeneron)
13.6.2.1. Target Patient Population
13.6.2.2. Sales Forecast (USD Billion)
13.6.2.3. Net Present Value (USD Billion)
13.6.2.4. Value Creation Analysis
13.6.3. RG6107 (Ruconest)
13.6.3.1. Target Patient Population
13.6.3.2. Sales Forecast (USD Billion)
13.6.3.3. Net Present Value (USD Billion)
13.6.3.4. Value Creation Analysis
13.6.4. rVA576 (Akari Therapeutics)
13.6.4.1. Target Patient Population
13.6.4.2. Sales Forecast (USD Billion)
13.6.4.3. Net Present Value (USD Billion)
13.6.4.4. Value Creation Analysis
13.6.5. SAR445088 (Sanofi)
13.6.5.1. Target Patient Population
13.6.5.2. Sales Forecast (USD Billion)
13.6.5.3. Net Present Value (USD Billion)
13.6.5.4. Value Creation Analysis
13.6.6. Soliris (Alexion Pharmaceuticals)
13.6.6.1. Target Patient Population
13.6.6.2. Sales Forecast (USD Billion)
13.6.6.3. Net Present Value (USD Billion)
13.6.6.4. Value Creation Analysis
13.6.7. Sutimlimab (Bioverativ)
13.6.7.1. Target Patient Population
13.6.7.2. Sales Forecast (USD Billion)
13.6.7.3. Net Present Value (USD Billion)
13.6.7.4. Value Creation Analysis
13.6.8. Vilobelimab (InflaRx)
13.6.8.1. Target Patient Population
13.6.8.2. Sales Forecast (USD Billion)
13.6.8.3. Net Present Value (USD Billion)
13.6.8.4. Value Creation Analysis
13.6.9. Zilucoplan (UCB)
13.6.9.1. Target Patient Population
13.6.9.2. Sales Forecast (USD Billion)
13.6.9.3. Net Present Value (USD Billion)
13.6.9.4. Value Creation Analysis

13.7. Summary: Phase III Drugs

14. EXPERT OPINION
14.1. New York Oncology Hematology
14.1.1. Overview of Organization
14.1.2. Expert Opinion: Mihir Raval (Physician)

14.2. Cedars-Sinai Tower Hematology Oncology Medical
14.2.1. Overview of Organization
14.2.2. Expert Opinion: Jeremy Lorber (Hematologist Oncologist)

14.3. Weill Cornell Medical College
14.3.1. Overview of Organization
14.3.2. Expert Opinion: Jeffrey Conrad Laurence (Senior Scientific Consultant)

14.4. Leiden University Medical Center
14.4.1. Overview of Organization
14.4.2. Expert Opinion: YKO (Onno) Teng (Nephrology Clinician-Scientist

14.5. Lund University
14.5.1. Overview of Organization
14.5.2. Expert Opinion: Mårten Segelmark (Professor of Nephrology)

15. APPENDIX 1: LIST OF FIGURES AND TABLES

16. APPNEDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Immune Cells Involved in Complement System
Figure 3.2 Role of Complement in Homeostasis and Stress Conditions
Figure 3.3 Activation of Complement System
Figure 3.4 Steps in Complement Activation
Figure 3.5 Pathways of Complement System
Figure 3.6 Consequences of a Dysregulated Complement System
Figure 3.7 Types of Complement Therapeutics
Figure 3.8 Limitations of Complement Therapeutics
Figure 3.9 Future of Next Generation Complement Therapeutics
Figure 4.1 Next Generation Complement Therapeutics: Distribution by Status of Development
Figure 4.2 Next Generation Complement Therapeutics: Distribution by Type of Molecule
Figure 4.3 Next Generation Complement Therapeutics: Distribution by Status of Development and Type of Molecule
Figure 4.4 Next Generation Complement Therapeutics: Distribution by Type of Drug
Figure 4.5 Next Generation Complement Therapeutics: Distribution by Biological Target
Figure 4.6 Next Generation Complement Therapeutics: Distribution by Target Pathway
Figure 4.7 Next Generation Complement Therapeutics: Distribution by Mechanism of Action
Figure 4.8 Next Generation Complement Therapeutics: Distribution by Mechanism of Action and Target Pathway
Figure 4.9 Next Generation Complement Therapeutics: Distribution by Target Disease Indication(s)
Figure 4.10 Next Generation Complement Therapeutics: Distribution by Status of Development and Target Disease Indication(s)
Figure 4.11 Next Generation Complement Therapeutics: Distribution by Therapeutic Area
Figure 4.12 Next Generation Complement Therapeutics: Distribution by Therapeutic Area and Type of Molecule
Figure 4.13 Next Generation Complement Therapeutics: Distribution by Route of Administration
Figure 4.14 Next Generation Complement Therapeutics: Distribution by Type of Therapy
Figure 4.15 Next Generation Complement Therapeutics: Distribution by Dosing Frequency
Figure 4.16 Grid Analysis: Distribution by Type of Therapy, Type of Molecule, Route of Administration and Mechanism of Action
Figure 4.17 Next Generation Complement Therapeutics: Distribution by Special Designation
Figure 4.18 Next Generation Complement Therapeutics Developers: Distribution by Year of Establishment
Figure 4.19 Next Generation Complement Therapeutics Developers: Distribution by Company Size
Figure 4.20 Next Generation Complement Therapeutics Developers: Distribution by Region of Headquarters
Figure 4.21 Next Generation Complement Therapeutics Developers: Distribution by Company Size and Region of Headquarters
Figure 4.22 Leading Players: Distribution by Number of Therapeutics
Figure 5.1 Amgen: Financial Information
Figure 5.2 CSL Behring: Financial Information
Figure 5.3 Innovent Biologics: Financial Information
Figure 5.4 Novartis: Financial Information
Figure 5.5 Regeneron: Financial Information
Figure 5.6 Roche: Financial Information
Figure 5.7 Sanofi: Financial Information
Figure 5.8 Takeda: Financial Information
Figure 5.9 UCB: Financial Information
Figure 6.1 Clinical Trial Analysis: Distribution by Trial Status
Figure 6.2 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, (Pre-2016-2021)
Figure 6.3 Clinical Trial Analysis: Distribution by Trial Registration Year and Status, (Pre-2001-2021)
Figure 6.4 Clinical Trial Analysis: Distribution by Trial Phase
Figure 6.5 Clinical Trial Analysis: Distribution by Trial Phase and Patients Enrolled
Figure 6.6 Clinical Trial Analysis: Distribution by Trial Registration Year and Patients Enrolled
Figure 6.7 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 6.8 Clinical Trial Analysis: Distribution by Type of Study
Figure 6.9 Clinical Trial Analysis: Distribution by Study Design
Figure 6.10 Most Active Industry Players: Distribution by Number of Trials
Figure 6.11 Most Active Non-Industry Players: Distribution by Number of Trials
Figure 6.12 Clinical Trial Analysis: Distribution by Disease Indication
Figure 6.13 Most Popular Therapeutic Areas: Distribution by Number of Trials
Figure 6.14 Clinical Trial Analysis: Distribution by Type of Treatment
Figure 6.15 Clinical Trial Analysis: Distribution by Type of Drug
Figure 6.16 Word Cloud Analysis: Emerging Focus Areas
Figure 6.17 Clinical Trial Analysis: Distribution by Top Indications and Phase of the Trial
Figure 6.18 Clinical Trial Analysis: Distribution by Top Indications and Leading Industry Players
Figure 6.19 Clinical Trial Analysis: Distribution by Trial Location
Figure 6.20 Clinical Trial Analysis: Distribution by Geography and Trial Status
Figure 7.1 Publication Analysis: Distribution by Year of Publication
Figure 7.2 Word Cloud Analysis: Emerging Focus Areas
Figure 7.3 Top Authors: Distribution by Number of Publications
Figure 7.4 Key Journals: Distribution by Number of Publications
Figure 7.5 Key Journals: Distribution by Impact Factor
Figure 7.6 Popular Indications: Distribution by Number of Publications
Figure 7.7 Popular Therapeutic Areas: Distribution by Number of Publications
Figure 8.1 Grant Analysis: Distribution by Year of Grants Awarded
Figure 8.2 Grant Analysis: Distribution by Amount Awarded
Figure 8.3 Grant Analysis: Distribution by Funding Institute Center
Figure 8.4 Grant Analysis: Distribution by Support Period
Figure 8.5 Grant Analysis: Distribution by Funding Institute Center and Support Period
Figure 8.6 Grant Analysis: Distribution by Type of Grant
Figure 8.7 Grant Analysis: Distribution by Activity Code
Figure 8.8 Popular Recipient Organizations: Distribution by Number of Grants
Figure 8.9 Popular Recipient Organizations: Distribution by Amount Awarded
Figure 8.10 Popular NIH Departments: Distribution by Number of Grants
Figure 8.11 Grant Analysis: Distribution by Study Section
Figure 8.12 Grant Analysis: Distribution by Type of Recipient Organization
Figure 8.13 Word Cloud Analysis: Emerging Focus Areas
Figure 8.14 Grants Analysis: Distribution by Purpose of Grant
Figure 8.15 Prominent Program Officers: Distribution by Number of Grants
Figure 8.16 Grant Analysis: Distribution by Location of Recipient Organizations
Figure 9.1 Patent Analysis: Distribution by Patent Publication Year
Figure 9.2 Patent Analysis: Year-wise Distribution of Granted Patents
Figure 9.3 Patent Analysis: Distribution by Type of Patent
Figure 9.4 Patent Analysis: Distribution by Granted Patents and Patent Applications
Figure 9.5 Patent Analysis: Distribution by Geography
Figure 9.6 Patent Analysis: Distribution by CPC Symbols
Figure 9.7 Patent Analysis: Distribution by Type of Applicant
Figure 9.8 Patent Analysis: Distribution of Patents by Age
Figure 9.9 Word Cloud Analysis: Emerging Focus Areas
Figure 9.10 Leading Industry Players: Distribution by Number of Patents
Figure 9.11 Leading Non-Industry Players: Distribution by Number of Patents
Figure 9.12 Leading Individual Assignees: Distribution by Number of Patents
Figure 9.13 Leading Players: Benchmarking by Patent Characteristics (CPC Symbols)
Figure 9.14 Patent Valuation: Distribution by Relative Valuation
Figure 10.1 Partnerships and Collaborations: Distribution by Year-wise Trend of Partnership
Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 10.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 10.4 Most Popular Drug: Distribution by Number of Partnerships
Figure 10.5 Partnerships and Collaborations: Distribution by Biological Target
Figure 10.6 Partnerships and Collaborations: Distribution by Target Pathway
Figure 10.7 Word Cloud Analysis: Emerging Focus Areas
Figure 10.8 Partnerships and Collaborations: Distribution by Drug and Type of Partnership
Figure 10.9 Partnerships and Collaborations: Distribution by Type of Partner
Figure 10.10 Partnerships and Collaborations: Distribution by Popular Disease Indication
Figure 10.11 Partnerships and Collaborations: Distribution by Popular Disease Indication and Type of Partnership
Figure 10.12 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 10.13 Partnerships and Collaborations: Distribution by Therapeutic Area and Type of Partnership
Figure 10.14 Regional Distribution of Partnerships
Figure 10.15 Intercontinental and Intracontinental Agreements
Figure 11.1 Funding and Investments: Cumulative Year-wise Trend
Figure 11.2 Funding and Investments: Distribution by Amount Invested per Year
Figure 11.3 Funding and Investments: Distribution by Type of Funding and Year of Establishment
Figure 11.4 Funding and Investments: Distribution of Instances by Type of Funding
Figure 11.5 Funding and Investments: Distribution of Amount Invested by Type of Funding
Figure 11.6 Funding and Investments: Distribution by Year, Type of Funding and Amount Invested
Figure 11.7 Most Active Investors: Distribution by Number of Instances
Figure 11.8 Most Active Players: Distribution by Number of Funding Instances
Figure 11.9 Most Active Players: Distribution by Amount Raised
Figure 11.10 Funding and Investments: Distribution of Amount by Drug
Figure 11.11 Funding and Investments: Distribution of Number of Instances by Drug
Figure 11.12 Funding and Investments: Summary of Investments
Figure 12.1 Distribution by Supplier Strength
Figure 12.2 Distribution by Portfolio Strength
Figure 12.3 Distribution by Portfolio Diversity
Figure 12.4 Benchmarking: Spider Web Analysis
Figure 12.5 Benchmarking: Harvey Ball Analysis
Figure 12.6 Benchmarking: Wind Rose Chart
Figure 13.1 Global Next Generation Complement Therapeutics Market, 2022-2035 (USD Billion)
Figure 13.2 Global Next Generation Complement Therapeutics Market for Marketed Drugs, 2022-2035 (USD Billion)
Figure 13.3 Next Generation Complement Therapeutics Market for Marketed Drugs, 2022-2035 (USD Billion): Distribution by Target Disease Indication
Figure 13.4 Next Generation Complement Therapeutics Market for Paroxysmal Nocturnal Hemoglobinuria, 2022-2035 (USD Billion)
Figure 13.5 Next Generation Complement Therapeutics Market for Hereditary Angioedema, 2022-2035 (USD Billion)
Figure 13.6 Next Generation Complement Therapeutics Market for Marketed Drugs, 2022-2035 (USD Billion): Distribution by Type of Molecule
Figure 13.7 Next Generation Complement Therapeutics Market for Biologics, 2022-2035 (USD Billion)
Figure 13.8 Next Generation Complement Therapeutics Market for Small Molecules, 2022-2035 (USD Billion)
Figure 13.9 Next Generation Complement Therapeutics Market for Marketed Drugs, 2022-2035 (USD Billion): Distribution by Target Pathway
Figure 13.10 Next Generation Complement Therapeutics Market for Terminal Pathway, 2022-2035 (USD Billion)
Figure 13.11 Next Generation Complement Therapeutics Market for Classical Pathway, 2022-2035 (USD Billion)
Figure 13.12 Next Generation Complement Therapeutics Market for Alternate Pathway, 2022-2035 (USD Billion)
Figure 13.13 Next Generation Complement Therapeutics Market for Lectin Pathway, 2022-2035 (USD Billion)
Figure 13.14 Next Generation Complement Therapeutics Market for Marketed Drugs, 2022-2035 (USD Billion): Distribution by Type of Therapy
Figure 13.15 Next Generation Complement Therapeutics Market for Monotherapy, 2022-2035 (USD Billion)
Figure 13.16 Next Generation Complement Therapeutics Market for Combination Therapy, 2022-2035 (USD Billion)
Figure 13.17 Next Generation Complement Therapeutics Market for Marketed Drugs, 2022-2035 (USD Billion): Distribution by Route of Administration
Figure 13.18 Next Generation Complement Therapeutics Market for Intravenous Drugs, 2022-2035 (USD Billion)
Figure 13.19 Next Generation Complement Therapeutics Market for Subcutaneous Drugs, 2022-2035 (USD Billion)
Figure 13.20 Next Generation Complement Therapeutics Market for Oral Drugs, 2022-2035 (USD Billion)
Figure 13.21 Berinert Sales Forecast, 2022-2035 (USD Billion)
Figure 13.22 EMPAVELI Sales Forecast, 2022-2035 (USD Billion)
Figure 13.23 ORLADEYO Sales Forecast, 2022-2035 (USD Billion)
Figure 13.24 Ruconest Sales Forecast, 2022-2035 (USD Billion)
Figure 13.25 Soliris Sales Forecast, 2022-2035 (USD Billion)
Figure 13.26 Takhzyro Sales Forecast, 2022-2035 (USD Billion)
Figure 13.27 Ultomiris Sales Forecast, 2022-2035 (USD Billion)
Figure 13.28 Global Next Generation Complement Therapeutics Market for Phase III Drugs, 2022-2035 (USD Billion)
Figure 13.29 Next Generation Complement Therapeutics Market for Phase III Drugs, 2022-2035 (USD Billion): Distribution by Target Disease Indication
Figure 13.30 Next Generation Complement Therapeutics Market for Atypical Hemolytic Uremic Syndrome, 2022-2035 (USD Billion)
Figure 13.31 Next Generation Complement Therapeutics Market for Cardiac Transplantation Rejection, 2022-2035 (USD Billion)
Figure 13.32 Next Generation Complement Therapeutics Market for Cold Agglutinin Disease, 2022-2035 (USD Billion)
Figure 13.33 Next Generation Complement Therapeutics Market for COVID-19, 2022-2035 (USD Billion)
Figure 13.34 Next Generation Complement Therapeutics Market for Guillain-Barre Syndrome, 2022-2035 (USD Billion)
Figure 13.35 Next Generation Complement Therapeutics Market for Generalized Myasthenia Gravis, 2022-2035 (USD Billion)
Figure 13.36 Next Generation Complement Therapeutics Market for Neuromyelitis Optica, 2022-2035 (USD Billion)
Figure 13.37 Next Generation Complement Therapeutics Market for Paroxysmal Nocturnal Hemoglobinuria, 2022-2035 (USD Billion)
Figure 13.38 Next Generation Complement Therapeutics Market for Phase III Drugs, 2022-2035 (USD Billion): Distribution by Therapeutic Area
Figure 13.39 Next Generation Complement Therapeutics Market for Cardiovascular Disorders, 2022-2035 (USD Billion)
Figure 13.40 Next Generation Complement Therapeutics Market for Hematological and Vascular Disorders, 2022-2035 (USD Billion)
Figure 13.41 Next Generation Complement Therapeutics Market for Infectious Diseases, 2022-2035 (USD Billion)
Figure 13.42 Next Generation Complement Therapeutics Market for Neurological Disorders, 2022-2035 (USD Billion)
Figure 13.43 Next Generation Complement Therapeutics Market for Neuromuscular Disorders, 2022-2035 (USD Billion)
Figure 13.44 Next Generation Complement Therapeutics Market for Genetic Disorders, 2022-2035 (USD Billion)
Figure 13.45 Next Generation Complement Therapeutics Market for Phase III Drugs, 2022-2035 (USD Billion): Distribution by Target Pathway
Figure 13.46 Next Generation Complement Therapeutics Market for Terminal Pathway, 2022-2035 (USD Billion)
Figure 13.47 Next Generation Complement Therapeutics Market for Lectin Pathway, 2022-2035 (USD Billion)
Figure 13.48 Next Generation Complement Therapeutics Market for Classical Pathway, 2022-2035 (USD Billion)
Figure 13.49 Next Generation Complement Therapeutics Market for Phase III Drugs, 2022-2035 (USD Billion): Distribution by Type of Therapy
Figure 13.50 Next Generation Complement Therapeutics Market for Monotherapy, 2022-2035 (USD Billion)
Figure 13.51 Next Generation Complement Therapeutics Market for Combination Therapy, 2022-2035 (USD Billion)
Figure 13.52 Next Generation Complement Therapeutics Market for Phase III Drugs, 2022-2035 (USD Billion): Distribution by Route of Administration
Figure 13.53 Next Generation Complement Therapeutics Market for Intravenous Drugs, 2022-2035 (USD Billion)
Figure 13.54 Next Generation Complement Therapeutics Market for Subcutaneous Drugs, 2022-2035 (USD Billion)
Figure 13.55 Next Generation Complement Therapeutics Market for Phase III Drugs, 2022-2035 (USD Billion): Distribution by Geography
Figure 13.56 Next Generation Complement Therapeutics Market in North America, 2022-2035 (USD Billion)
Figure 13.57 Next Generation Complement Therapeutics Market in US, 2022-2035 (USD Billion)
Figure 13.58 Next Generation Complement Therapeutics Market in Canada, 2022-2035 (USD Billion)
Figure 13.59 Next Generation Complement Therapeutics Market in Europe, 2022-2035 (USD Billion)
Figure 13.60 Next Generation Complement Therapeutics Market in UK, 2022-2035 (USD Billion)
Figure 13.61 Next Generation Complement Therapeutics Market in Germany, 2022-2035 (USD Billion)
Figure 13.62 Next Generation Complement Therapeutics Market in France, 2022-2035 (USD Billion)
Figure 13.63 Next Generation Complement Therapeutics Market in Italy, 2022-2035 (USD Billion)
Figure 13.64 Next Generation Complement Therapeutics Market in Spain, 2022-2035 (USD Billion)
Figure 13.65 Next Generation Complement Therapeutics Market in Asia Pacific, 2022-2035 (USD Billion)
Figure 13.66 Next Generation Complement Therapeutics Market in Australia, 2022-2035 (USD Billion)
Figure 13.67 Next Generation Complement Therapeutics Market in Japan, 2022-2035 (USD Billion)
Figure 13.68 Next Generation Complement Therapeutics Market in China, 2022-2035 (USD Billion)
Figure 13.69 Next Generation Complement Therapeutics Market in India, 2022-2035 (USD Billion)
Figure 13.70 Narsoplimab: Target Patient Population
Figure 13.71 Narsoplimab Sales Forecast, 2022-2035 (USD Billion)
Figure 13.72 REGN3918: Target Patient Population
Figure 13.73 REGN3918 Sales Forecast, 2022-2035 (USD Billion)
Figure 13.74 RG6107: Target Patient Population
Figure 13.75 RG6107 Sales Forecast, 2022-2035 (USD Billion)
Figure 13.76 rVA576: Target Patient Population
Figure 13.77 rVA576 Sales Forecast, 2022-2035 (USD Billion)
Figure 13.78 SAR445088: Target Patient Population
Figure 13.79 SAR445088 Sales Forecast, 2022-2035 (USD Billion)
Figure 13.80 Soliris: Target Patient Population
Figure 13.81 Soliris Sales Forecast, 2022-2035 (USD Billion)
Figure 13.82 Sutimlimab: Target Patient Population
Figure 13.83 Sutimlimab Sales Forecast, 2022-2035 (USD Billion)
Figure 13.84 Vilobelimab: Target Patient Population
Figure 13.85 Vilobelimab Sales Forecast, 2022-2035 (USD Billion)
Figure 13.86 Zilucoplan: Target Patient Population
Figure 13.87 Zilucoplan Sales Forecast, 2022-2035 (USD Billion)

List Of Tables

Table 3.1 Sources of Key Complement Proteins
Table 3.2 Functions of Complement Proteins of Classical Pathway
Table 3.3 Diseases Related to Defects in Complement Proteins
Table 4.1 Next Generation Complement Therapeutics: Development Pipeline
Table 4.2 List of Drugs with Special Designations
Table 4.3 Next Generation Complement Therapeutics: List of Developers
Table 5.1 Amgen: Product Portfolio
Table 5.2 Recent Developments and Future Outlook
Table 5.3 CSL Behring: Product Portfolio
Table 5.4 Recent Developments and Future Outlook
Table 5.5 Innovent Biologics: Product Portfolio
Table 5.6 Recent Developments and Future Outlook
Table 5.7 Novartis: Product Portfolio
Table 5.8 Recent Developments and Future Outlook
Table 5.9 Regeneron: Product Portfolio
Table 5.10 Recent Developments and Future Outlook
Table 5.11 Roche: Product Portfolio
Table 5.12 Recent Developments and Future Outlook
Table 5.13 Sanofi: Product Portfolio
Table 5.14 Recent Developments and Future Outlook
Table 5.15 Takeda: Product Portfolio
Table 5.16 Recent Developments and Future Outlook
Table 5.17 UCB: Product Portfolio
Table 5.18 Recent Developments and Future Outlook
Table 6.1 Next Generation Complement Therapeutics: List of Clinical Trials, (till October 2021)
Table 7.1 Next Generation Complement Therapeutics: List of Publications, (till November 2021)
Table 9.1 Next Generation Complement Therapeutics: List of Patents, (till November 2021)
Table 10.1 Next Generation Complement Therapeutics: List of Partnerships and Collaborations, 2014-2021 (till November)
Table 11.1 Next Generation Complement Therapeutics: List of Funding and Investments (till November 2021)
Table 12.1 Big Pharma Players: Information on Revenues Generated in 2021
Table 13.1 Next Generation Complement Therapeutics: List of Forecasted Marketed Drugs
Table 13.2 Next Generation Complement Therapeutics: List of Forecasted Phase III Drugs
Table 13.3 Summary: Phase III Drugs
 

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  1. AbbVie
  2. Achillion Pharmaceuticals (acquired by Alexion Pharmaceuticals)
  3. Adage Capital Management
  4. ADIENNE
  5. Adverum Biotechnologies
  6. AffaMed Therapeutics
  7. AJU IB Investment
  8. Akari Therapeutics
  9. Alexion Pharmaceuticals
  10. Ally Bridge
  11. Alnylam Pharmaceuticals
  12. Alsonex
  13. Amgen
  14. Amyndas Pharmaceuticals
  15. Annexon Biosciences
  16. Apellis Pharmaceuticals
  17. Aquilo Capital
  18. argenx
  19. Assistance Publique - Hôpitaux de Paris (AP-HP)
  20. AstraZeneca
  21. Athyrium Capital Management
  22. Attune Pharmaceuticals
  23. Bain Capital Life Sciences
  24. Bayer
  25. Beam Therapeutics
  26. BioCryst Pharmaceuticals
  27. Biogen
  28. BioMarin Pharmaceutical
  29. Bioverativ (acquired by Sanofi)
  30. BlackRock
  31. Blackstone Life Sciences (BXLS)
  32. Boston University Medical Campus (BUMC)
  33. Boxer Capital
  34. Bristol Myers Squibb
  35. Broad Institute
  36. Broteio Pharma
  37. Burrage Capital Management
  38. Camurus
  39. CANbridge Pharmaceuticals
  40. Catalyst Biosciences
  41. Center for Research on Inflammatory Diseases (CRID)
  42. ChemoCentryx
  43. China Life Private Equity Investment
  44. Chugai Pharmaceutical
  45. Cincinnati Children's Hospital Medical Center
  46. Clarus (acquired by Blackstone)
  47. Clinigen
  48. Clough Capital Partners
  49. Columbia University Health Sciences
  50. Complement Pharma
  51. Cormorant Asset Management
  52. Correlation Ventures
  53. CRG Capital Partners
  54. CSL Behring
  55. CVie Therapeutics
  56. DAFNA Capital Management
  57. Deerfield Management
  58. Dicerna Pharmaceuticals
  59. Dompé Pharmaceuticals
  60. Duke University
  61. Dyax (acquired by Shire)
  62. East West Bank
  63. Epidarex Capital
  64. Eventide Asset Management
  65. Farallon Capital Management
  66. Federal Ministry of Education and Research (Germany)
  67. Federal Ministry of Health (Germany)
  68. Foresite Capital
  69. F-Prime Capital Partners
  70. Frazier Life Sciences
  71. Future Industry Investment Fund
  72. Genentech
  73. GENERIUM
  74. Genzyme (a subsidiary of Sanofi)
  75. GlaxoSmithKline
  76. Halozyme Therapeutics
  77. Harvard College
  78. Hemera Biosciences
  79. Hercules Capital
  80. Hillhouse Capital
  81. Icahn School of Medicine at Mount Sinai (ISMMS)
  82. I-Mab
  83. InflaRx
  84. Innate Pharma
  85. Innovent Biologics
  86. Ionis Pharmaceuticals
  87. IQVIA
  88. ISU ABXIS
  89. Iveric Bio
  90. Janus Henderson Investors
  91. Johns Hopkins University
  92. KalVista Pharmaceuticals
  93. Karolinska Institutet
  94. Kissei Pharmaceutical
  95. Legend Capital
  96. LifeSci Venture Partners
  97. Lilly Asia Ventures
  98. Logos Capital
  99. Longwood Fund
  100. Mallinckrodt
  101. Massachusetts General Hospital
  102. MidCap Financial
  103. Milestone Capital Advisors
  104. Morningside Ventures
  105. MorphoSys
  106. MPM Capital
  107. National Cancer Institute (NCI)
  108. National Institute of Allergy and Infectious Diseases (NIAID)
  109. National Institute of Mental Health (NIMH)
  110. National Institutes of Health Clinical Center (NIHCC)
  111. Neopharm
  112. New Enterprise Associates (NEA)
  113. NewBridge Pharmaceuticals
  114. Nichi-Iko Pharmaceutical
  115. Novartis
  116. Novartis Venture Fund
  117. NovelMed Therapeutics
  118. Novo
  119. NOXXON Pharma
  120. NYU Grossman School of Medicine
  121. Omeros
  122. OMERS
  123. OrbiMed Advisors
  124. Oxford Finance
  125. PANTHERx
  126. Parexel
  127. Paulson Investment
  128. Perceptive Advisors
  129. Pharmasyntez
  130. Pharming
  131. Ping An
  132. Prothix
  133. Qiming Venture Partners
  134. Quartesian
  135. QVT Financial
  136. RA Capital Management
  137. Ra Pharmaceuticals (acquired by UCB)
  138. Redmile
  139. Regeneron
  140. Regenesance
  141. Roche
  142. Rock Springs Capital
  143. Royalty Pharma
  144. RPC Pharma
  145. RTW Investments
  146. Samsung Bioepis
  147. Sanofi
  148. Satter Investment Management
  149. Satter Medical Technology Partners
  150. Sectoral Asset Management
  151. Selexis
  152. SFJ Pharmaceuticals
  153. Shire (acquired by Takeda)
  154. Silence Therapeutics
  155. Sobi
  156. Sofinnova
  157. Staidson Hongkong Investment
  158. Stanford University
  159. Surveyor Capital
  160. SV Life Sciences
  161. Taikang Insurance
  162. Takeda
  163. Tang Capital Management
  164. Tasly Biopharmaceuticals
  165. Temasek
  166. TF Capital
  167. Torii Pharmaceutical
  168. UCB
  169. UC San Diego
  170. University of California, San Francisco
  171. University of Cambridge
  172. University of Colorado
  173. University of Leicester
  174. University of Michigan
  175. University of North Carolina at Chapel Hill
  176. University of Pennsylvania
  177. University of Pittsburgh
  178. venBio Global Strategic Fund
  179. venBio Select
  180. Venrock
  181. Vifor Pharma
  182. Vivo Capital
  183. Washington University
  184. WuXi Biologics
  185. Xencor
  186. Yale University
  187. Zealand Pharma

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 8) n a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com